• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INC Research launches its IPO

INC Research launches its IPO

November 10, 2014
CenterWatch Staff

Global CRO INC Research launched its initial public offering today, raising $150 million by selling just over 8.1 million shares at $18.50 per share—the middle of the expected $17-$20 range. The stock climbed 9% in early trading past $20.75 before settling to $20 by late afternoon.

Founded more than 20 years ago, the Raleigh, N.C.-based company, focused on phase I to phase IV clinical development services, had been working toward today’s IPO launch since early summer.

“Yes, we’re very happy as we’ve reached an important milestone for INC, which will enable us to pay down debt [$592.5 million as of June 30] and still have about $100 million in cash,” said Jamie Macdonald, CEO of INC Research Holdings. “This IPO gives us options to possibly pay down debt further, consider a secondary offering from the original shareholders and make some additional acquisitions.”

In 2010, INC Research was acquired by two large private equity groups—Avista Capital Partners and affiliates of the Ontario Teachers’ Pension Plan—for $600 million. Since 2011, INC has grown with recent profitability. The improved balance sheet played a role in the decision to file for an IPO.

Company officials said they have added more than 650 people in the past 20 months, now employing 5,500 worldwide, including 2,600 in the U.S. and Canada. INC added 40 employees when it acquired MEK Consulting, a CRO based in the Middle East and North Africa, in March, after working with MEK for more than 10 years. In 2011, INC made a major acquisition of Kendle, a publicly traded CRO based in Cincinnati, for $232 million in cash. Macdonald joined INC as chief operating officer from Kendle, and subsequently became CEO.

“We would like to add more companies if they fit the INC model, as we have a good geographic footprint in the clinical development space,” said Macdonald. “The overall market for R&D in the clinical research space is quite good. There’s a lot of industry funding and growth from biotechnology companies, which benefits the CRO industry as outsourcing continues.”

He cited several CROs in recent years that have turned to Wall Street, most notably Quintiles, based in Durham, N.C., which raised $947 million in May 2013. Macdonald acknowledged another Raleigh company, PRA Health Sciences, a substantially larger CRO, seeks to raise as much as $375 million in an upcoming IPO.

CROs are part of a U.S. IPO market that has been booming, as stock prices remain high and market volatility is relatively subdued. Overall, investors are eager for new growth opportunities including CROs, and many that have gone public this year have seen strong demand. Quintiles shares have risen 20% this year.

“For us it’s business as usual as our key areas of focus going forward are process improvements, technology and continuing relationships with investigative sites that support patients and site communities,” said Macdonald.

INC Research is traded on the Nasdaq Global Market under the ticker symbol INCR.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing